Adagene Inc. (ADAG, Financial), a clinical-stage biopharmaceutical company, experienced a significant stock movement with a 5.43% surge in its share price. The stock is currently priced at $2.33 per share with a trading volume of 10,385 shares, indicating a turnover rate of 0.02% and a price fluctuation amplitude of 4.98%.
Recent financial reports reveal that Adagene Inc. recorded no operating revenue, a net loss of $17.01 million, and an earnings per share (EPS) of -$0.39. The company reported a gross profit of $0.00 and holds a price-to-earnings ratio of -3.14. Despite these figures, both participating institutions have provided a "buy" recommendation for the stock, with no ratings for "hold" or "sell."
Within the biotechnology sector, which overall declined by 0.20%, several stocks showed notable performances. Stocks such as Bright Minds Biosciences Inc. led gains, while others like Salarius Pharmaceuticals, Inc., and Aditxt, Inc. were highly active, with turnover rates significantly above industry norms. Large price fluctuations were also observed in stocks like Psyence Biomedical Ltd and Apollomics Inc.
Adagene Inc. specializes in developing transformative cancer immunotherapies based on antibodies, focusing on generating therapeutic candidate antibodies with functional epitopes and cross-reactivity across multiple species.
